In 2016, Ipsen’s R&D expenditure totaled close to €209 million, representing more than 13% of Group sales.

 

Ipsen R&D has a valuable pipeline that aims at the discovery of potential highly differentiated and competitive products in neurosciences, oncology and rare diseases.

tableau Pipeline
Last update 30/11/2017